Study S000275

Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07772960
Acronym: SEMA AUD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 90
Start: 2026-10-01
Primary completion: 2031-10-31
Lead sponsor: Yale University
Conditions: Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30)
Interventions: OTHER:Placebo; DRUG:Semaglutide 1.0 mg; DRUG:Semaglutide 2.0 mg
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: NIH:R01AA032779

Registered primary outcomes

Alcohol use days [20 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004902	Alterations in glucose and insulin resistance following stress and alcohol cues predict alcohol craving in those with AUD and obesity: A preliminary study. Harvanek ZM, Alcohol, clinical & experimental research	2026	Other trial	PMID 42101823 DOI	registry reference BACKGROUND:42101823